Iranian
Biomedical Journal
Volume 28, Issue 7 (Special Issue 2024)
IBJ 2024, 28(7): 273-273 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Golkar Z, Akhavan A, Shekarchizadeh M. New Management for a Case of Severe Coronary Spasm Associated with Fluorouracil Chemotherapy. IBJ 2024; 28 (7) :273-273
URL: http://ibj.pasteur.ac.ir/article-1-4707-en.html
URL: http://ibj.pasteur.ac.ir/article-1-4707-en.html
Abstract:
Introduction: Chemotherapy-induced coronary vasospasm is a rare yet severe complication that can hinder cancer treatment. Fluoropyrimidines, such as capecitabine and fluorouracil (5-FU), are commonly used for solid tumors like colorectal cancer and are the second most common chemotherapy agents linked to cardiac toxicity, including coronary vasospasm, with incidence rates up to 13%. The standard treatment involves discontinuing the fluoropyrimidine and administering nitrates and calcium channel blockers. However, continuing fluoropyrimidines might be necessary for treating cancer. Midazolam has been used to reduce spasms during coronary interventions but has not been reported for 5-FU-induced vasospasm until now.
Case Presentation: This case report describes a 71-year-old male with metastatic colorectal cancer who experienced recurrent coronary vasospasm during chemotherapy. Initially treated with FOLFOX, the patient had vasospasms managed with diltiazem and midazolam. Upon disease progression and increased carcinoembryonic antigen levels, treatment switched to FOLFIRI with cetuximab, followed by other regimens. Throughout these treatments, the patient continued to experience and manage chemotherapy-induced coronary vasospasm with diltiazem and midazolam. Despite these treatments, the patient's condition worsened, and he eventually succumbed to the disease.
Results: This case underscores the difficulty in balancing effective chemotherapy with managing severe side effects like coronary vasospasm. The cardiotoxicity mechanisms of 5-FU remain unclear, highlighting the need for further research. This report demonstrates the potential effectiveness of midazolam, suggesting a new approach for managing similar cases. Continuous monitoring and targeted strategies for cardiotoxicity prevention and management are essential.
Case Presentation: This case report describes a 71-year-old male with metastatic colorectal cancer who experienced recurrent coronary vasospasm during chemotherapy. Initially treated with FOLFOX, the patient had vasospasms managed with diltiazem and midazolam. Upon disease progression and increased carcinoembryonic antigen levels, treatment switched to FOLFIRI with cetuximab, followed by other regimens. Throughout these treatments, the patient continued to experience and manage chemotherapy-induced coronary vasospasm with diltiazem and midazolam. Despite these treatments, the patient's condition worsened, and he eventually succumbed to the disease.
Results: This case underscores the difficulty in balancing effective chemotherapy with managing severe side effects like coronary vasospasm. The cardiotoxicity mechanisms of 5-FU remain unclear, highlighting the need for further research. This report demonstrates the potential effectiveness of midazolam, suggesting a new approach for managing similar cases. Continuous monitoring and targeted strategies for cardiotoxicity prevention and management are essential.
Type of Study: Full Length/Original Article |
Subject:
Related Fields
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
IBJ is a member of Committee on Publication Ethics (COPE)
and follows its guidelines |
The articles of this journal are licensed under
a Creative Commons Attribution-NonDerivatives 4.0 International License. .png) |
 IBJ is owned and published by Pasteur Institute of Iran |